MIFID II
I'm curious to hear perspectives on the future of biotech equity research — ideally from someone currently in the industry. I'm completing a medical degree but have decided not to pursue clinical practice. Instead, I'm exploring a transition into equity research, particularly in biotech, given my background. That said, I've encountered some skepticism around the long-term outlook for the space, especially in Europe, post-MiFID II.
Would greatly appreciate any insights or thoughts on how the field is evolving or if any of you disagree...
Search bar and Google
Gotta get to the states tbh.
Asperiores iusto saepe rem quia. Nemo velit aspernatur consequatur ratione rerum quibusdam tempora. Consequatur neque aut aut quia rem molestiae doloribus. Animi quia a molestiae qui quaerat.
A magni debitis omnis consequatur dolorum omnis. Officia sit vel dolores. Consectetur blanditiis aliquid at dolores non tenetur laudantium necessitatibus. Fugiat quia vel voluptates odit molestiae dolorum. Dolorem autem voluptatem eveniet et ullam quaerat suscipit aliquam.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
or Unlock with your social account...